YONG LI to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications YONG LI has written about Antineoplastic Agents, Immunological.
Connection Strength
0.175
-
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020 01 30; 19(1):19.
Score: 0.140
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
Score: 0.034